Prentiss Smith & CO Inc Regenxbio Inc. Transaction History

Prentiss Smith & CO Inc

$148 Million
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 02, 2024	SELL	$12.89 - $20.82 $14,604 - $23,589	-1,133 Reduced 10.08%	10,107 $181,000
Q3 2023 Oct 24, 2023	BUY	$16.46 - $19.99 $185,010 - $224,687	11,240 New	11,240 $185,000
Q4 2022 Jan 31, 2023	SELL	$20.4 - $24.73 $3,121 - $3,783	-153 Reduced 1.6%	9,431 $213,000
Q3 2022 Oct 21, 2022	SELL	$22.29 - $35.04 $2,786 - $4,380	-125 Reduced 1.29%	9,584 $253,000
Q2 2022 Aug 12, 2022	SELL	$19.35 - $35.04 $19,350 - $35,040	-1,000 Reduced 9.34%	9,709 $240,000
Q1 2022 May 09, 2022	SELL	$24.62 - $34.31 $4,431 - $6,175	-180 Reduced 1.65%	10,709 $355,000
Q4 2021 Jan 28, 2022	SELL	$30.19 - $40.28 $3,019 - $4,028	-100 Reduced 0.91%	10,889 $356,000
Q2 2021 Jul 15, 2021	SELL	$32.46 - $40.48 $3,797 - $4,736	-117 Reduced 1.05%	10,989 $427,000
Q1 2021 Jun 21, 2021	SELL	$33.61 - $49.95 $22,518 - $33,466	-670 Reduced 5.69%	11,106 $379,000
Q4 2020 Feb 03, 2021	SELL	$26.52 - $49.35 $16,575 - $30,843	-625 Reduced 5.04%	11,776 $534,000
Q3 2020 Nov 02, 2020	BUY	$27.01 - $40.26 $486 - $724	18 Added 0.15%	12,401 $341,000
Q2 2020 Jul 13, 2020	BUY	$27.75 - $43.44 $4,218 - $6,602	152 Added 1.24%	12,383 $456,000
Q1 2020 Apr 29, 2020	BUY	$21.5 - $54.2 $4,300 - $10,840	200 Added 1.66%	12,231 $396,000
Q4 2019 Jan 21, 2020	BUY	$34.54 - $44.87 $152,839 - $198,549	4,425 Added 58.18%	12,031 $493,000
Q3 2019 Nov 06, 2019	BUY	$31.84 - $50.88 $1,783 - $2,849	56 Added 0.74%	7,606 $271,000
Q2 2019 Jul 19, 2019	BUY	$42.0 - $59.29 $317,100 - $447,639	7,550 New	7,550 $388,000
Q4 2018 Jan 15, 2019	SELL	$39.11 - $75.15 $26,203 - $50,350	-670 Closed	0 $0
Q2 2018 Jul 19, 2018	BUY	$27.2 - $74.35 $18,224 - $49,814	670 New	670 $48,000

Others Institutions Holding RGNX

# of Institutions

197

Shares Held

43.2M

Call Options Held

104K

Put Options Held

478K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $413M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prentiss Smith & CO Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prentiss Smith & CO Inc with notifications on news.

Account